论文部分内容阅读
用改良Ｓｐｅｒｒｙ自身底物法分别测定了３４例正常人及１５８例肾脏病患者的血清ＬＣＡＴ活性，此法简便、重复性好。联合ＨＤＬ－亚组份检测不失为一种观察各种疾病所致脂质代谢异常的敏感指标。本文测定结果表明，肾脏病患者的血清ＬＣＡＴ活性较正常组显著降低，差异非常显著，证实肾脏疾患时伴有脂酶活性障碍。而且还发现尿毒症、肾炎患者存在低ＨＤＬ血症，尤以ＨＤＬ３降低为明显，而肾病组ＨＤＬ升高，但无统计学意义。唯ＨＤＬ２升高，分别与正常组、尿毒症组及肾炎组比较均有显著意义。
Serum LCAT activity was measured in 34 normal subjects and 158 patients with renal disease by modified Sperry’s own substrate method. This method is simple and reproducible. Joint HDL-sub-component test is a sensitive indicator of abnormal lipid metabolism observed by various diseases. The results of this study showed that the serum LCAT activity of patients with kidney disease was significantly lower than the normal group, the difference was very significant, confirming the renal disorders associated with lipase activity disorders. But also found that uremia, nephritis patients with low HDL hyperlipidemia, especially HDL3 decreased significantly, while the HDL increased nephropathy group, but no statistically significant. Only HDL2 increased, respectively, with the normal group, uremia group and nephritis group were significant.